Gapping up
In reaction to strong earnings/guidance: LUB +5.4%, PACW +3.3%, DAL +2%, SJR +1%, UN +0.8%
M&A news: SNTA +29.2% (to merge with privately-held Madrigal Pharmaceuticals; will acquire Madrigal shares in exchange for ~253.9 mln newly issued shares of Synta common stock), PLCM +4.4% (Mitel (MITL) merger speculation)
Select oil/gas related names showing strength: SDRL +4.9%, WLL +2.4%, CHK +2.1%, MRO +0.9%
Other news: SUNE +75.6% (discloses completion of investigation by Audit Committee and Independent Directors), RPRX+17.8% (continued momentum higher), FMCC +8.9% (FHFA may release new plan to reduce borrower principal this week, according to WSJ), VSLR +8.4% (in sympathy with SUNE), ORPN +7.8% (scheduled to appear at American Academy of Neurology Annual Meeting tomorrow), CTIC +5.8% (continued strength), GLBL +5.3% (in sympathy with SUNE), WYNN +3.4% (CEO Steve Wynn acquires ~73k common shares), TERP +2.8% (in sympathy with SUNE), XON +2.4% (CDC concluded Zika causes microcephaly and other birth defects), FNMA +2.3% (FHFA may release new plan to reduce borrower principal this week, according to WSJ), EXPE +1.6% (favorable commentary on Wednesday's Mad Money), MNKD +1.2% (continued strength), LUV+1.1% (in sympathy with DAL (earnings))
Analyst comments: DDD +6.6% (upgraded to Buy from Underperform at BofA/Merrill), CMG +2.1% (upgraded to Overweight from Neutral at JP Morgan), INSY +2% (initiated with a Buy at Janney ), BAX +1.3% (upgraded to Overweight from Neutral at Piper Jaffray), IR +1.1% (upgraded to Buy from Neutral at Buckingham Research)
In reaction to strong earnings/guidance: LUB +5.4%, PACW +3.3%, DAL +2%, SJR +1%, UN +0.8%
M&A news: SNTA +29.2% (to merge with privately-held Madrigal Pharmaceuticals; will acquire Madrigal shares in exchange for ~253.9 mln newly issued shares of Synta common stock), PLCM +4.4% (Mitel (MITL) merger speculation)
Select oil/gas related names showing strength: SDRL +4.9%, WLL +2.4%, CHK +2.1%, MRO +0.9%
Other news: SUNE +75.6% (discloses completion of investigation by Audit Committee and Independent Directors), RPRX+17.8% (continued momentum higher), FMCC +8.9% (FHFA may release new plan to reduce borrower principal this week, according to WSJ), VSLR +8.4% (in sympathy with SUNE), ORPN +7.8% (scheduled to appear at American Academy of Neurology Annual Meeting tomorrow), CTIC +5.8% (continued strength), GLBL +5.3% (in sympathy with SUNE), WYNN +3.4% (CEO Steve Wynn acquires ~73k common shares), TERP +2.8% (in sympathy with SUNE), XON +2.4% (CDC concluded Zika causes microcephaly and other birth defects), FNMA +2.3% (FHFA may release new plan to reduce borrower principal this week, according to WSJ), EXPE +1.6% (favorable commentary on Wednesday's Mad Money), MNKD +1.2% (continued strength), LUV+1.1% (in sympathy with DAL (earnings))
Analyst comments: DDD +6.6% (upgraded to Buy from Underperform at BofA/Merrill), CMG +2.1% (upgraded to Overweight from Neutral at JP Morgan), INSY +2% (initiated with a Buy at Janney ), BAX +1.3% (upgraded to Overweight from Neutral at Piper Jaffray), IR +1.1% (upgraded to Buy from Neutral at Buckingham Research)